Sunday - April 5, 2026
Novartis IgAN Data in New England Journal of Medicine Show Fabhalta(R) Slowed Kidney Function Decline by 49.3%
March 31, 2026
BASEL, Switzerland, March 31 -- Novartis, a pharmaceutical company, issued the following news release on March 29, 2026:

* * *

Novartis IgAN data in New England Journal of Medicine show Fabhalta(R) slowed kidney function decline by 49.3%

* Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study1

* 40.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1

* . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products